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I N T R O D U C T I O N
One of the earliest discoveries of chronic nicotine expo-
sure was the observation of an increased number of 
nicotinic acetylcholine receptors (nAChRs; termed up-
regulation) (Marks et al., 1983; Schwartz and Kellar, 
1983; Breese et al., 1997; Mamede et al., 2007; Nashmi 
et al., 2007). Classically, up-regulation of nAChRs has 
been defined as an increase in nAChR protein, as iden-
tified by increased agonist binding (Marks et al., 1983; 
Benwell et al., 1988; Flores et al., 1992; Peng et al., 
1994), but we now define up-regulation as a change in 
receptor number, stoichiometry, and trafficking (Lester 
et al., 2009; Miwa et al., 2011). Often, an increase in 
total binding as opposed to cell surface binding has 
been reported. Therefore, up-regulation of nAChRs in-
volves an increase in nAChR abundance throughout 
the cell (ER, Golgi, etc.) and not exclusively on the 
plasma membrane (PM). There have been several hy-
potheses regarding the mechanism of up-regulation, 
but a consensus is emerging that nicotine acts inside the 
cell to enhance a critical step(s) in the maturation process 
Correspondence to Henry A. Lester: L e s t e r @ C a l t e c h . e d u 
Abbreviations used in this paper: COPI, coat protein complex I; ERES, 
ER exit sites; nAChR, nicotinic acetylcholine receptor; Neuro-2a, neuroblas-
toma 2a; NFRET, normalized Förster resonance energy transfer; PM, plasma 
membrane; PMID, PM integrated density; ROI, regions of interest; SEP, 
supercliptic-pHluorin; SNc, substantia nigra pars compacta; TIRFM, total 
internal reflection fluorescence microscopy; VTA, ventral tegmental area.
of nAChRs (Sallette et al., 2005). This intracellular en-
hancement process has been characterized as pharma-
cological chaperoning (Kuryatov et al., 2005; Lester et al., 
2009), and it occurs at the nanomolar concentrations 
thought to persist in the brain for hours after a person 
smokes. Research from many laboratories indicates that 
up-regulation of 42 nAChRs occurs through a similar 
process in human brains, animal brains, cultured neu-
rons, and clonal transfected cell lines (Nashmi et al., 
2007; Mukhin et al., 2008; Miwa et al., 2011; Srinivasan 
et al., 2011; Lester et al., 2012).
Up-regulation of nAChRs in response to chronic nic-
otine plays a major role in nicotine dependence and, 
perhaps, in the inverse correlation between a person’s 
history of tobacco use and his or her susceptibility to 
Parkinson’s disease (Ritz et al., 2007; Koob, 2009). Indi-
vidual deletions of the 4, 6, or 2 nAChR subunits 
are sufficient to block the self-administration of nicotine 
in mice (Pons et al., 2008), whereas the selective reexpres-
sion of these deleted subunits in the ventral tegmental 
area (VTA) is sufficient to reinstate self-administration 
of nicotine (Pons et al., 2008; Brunzell et al., 2010). 
Nicotine exploits a COPI-mediated process for chaperone-mediated 
up-regulation of its receptors
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Chronic exposure to nicotine up-regulates high sensitivity nicotinic acetylcholine receptors (nAChRs) in the brain. 
This up-regulation partially underlies addiction and may also contribute to protection against Parkinson’s disease. 
nAChRs containing the 6 subunit (6* nAChRs) are expressed in neurons in several brain regions, but comparatively 
little is known about the effect of chronic nicotine on these nAChRs. We report here that nicotine up-regulates 6* 
nAChRs in several mouse brain regions (substantia nigra pars compacta, ventral tegmental area, medial habenula, 
and superior colliculus) and in neuroblastoma 2a cells. We present evidence that a coat protein complex I (COPI)-
mediated process mediates this up-regulation of 6* or 4* nAChRs but does not participate in basal trafficking. 
We show that 623 nAChR up-regulation is prevented by mutating a putative COPI-binding motif in the 3 sub-
unit or by inhibiting COPI. Similarly, a COPI-dependent process is required for up-regulation of 42 nAChRs by 
chronic nicotine but not for basal trafficking. Mutation of the putative COPI-binding motif or inhibition of COPI 
also results in reduced normalized Förster resonance energy transfer between 623 nAChRs and COP subunits. 
The discovery that nicotine exploits a COPI-dependent process to chaperone high sensitivity nAChRs is novel and 
suggests that this may be a common mechanism in the up-regulation of nAChRs in response to chronic nicotine.
© 2014 Henderson et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publi-
cation date (see http://www.rupress.org/terms). After six months it is available under a 
Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, 
as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
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M A T E R I A L S  A N D  M E T H O D S
Reagents
The -COP antibody (rabbit polyclonal) was obtained from Abcam 
(AB2899). CI-976 and ()-nicotine hydrogen tartrate were ob-
tained from Sigma-Aldrich.
Mice and chronic nicotine administration
The construction of 6-GFP mice has been described previously 
(Mackey et al., 2012). All experiments were conducted in accor-
dance with the guidelines for care and use of animals provided by 
the National Institutes of Health, and protocols were approved by 
the Institutional Animal Care and Use Committee at the Califor-
nia Institute of Technology.
Chronic nicotine administration
Mice were kept on a standard 12-h light/dark cycle at 22°C and 
given food and water ad libitum. Chronic nicotine or saline was 
administered to mice using miniosmotic pumps (model 2002; 
Alzet). On the day of pump implantation, saline or ()-nicotine 
hydrogen tartrate (Sigma-Aldrich) was prepared freshly and loaded 
into the pump to deliver nicotine at 2 mg/kg/h or 0.4 mg/kg/h. 
This concentration provides maximal nAChR up-regulation and a 
peripheral blood concentration that is near the peak concentra-
tion found in the blood of human smokers (Marks et al., 2004). 
Surgical procedures for the pump implantation have been re-
ported previously (Nashmi et al., 2007).
Cell culture
Mouse neuroblastoma 2a (Neuro-2a) cells were cultured using 
standard techniques (Xiao et al., 2011). Cells were plated by add-
ing 90,000 cells to poly-d-lysine–coated 35-mm glass-bottom imag-
ing dishes (MatTek Corporation) and cultured in a humidified 
incubator (37°C, 95% air, 5% CO2). Cells were transfected with 
500 ng of each nAChR subunit plasmid and 250 ng GalT-mCherry 
or Sec24D-mCherry for assays. Plasmids were mixed with 250 µl 
Opti-MEM. Lipofectamine-2000 was separately added to 250 µl 
Opti-MEM. After 5 min at 24°C, DNA and Lipofectamine solu-
tions were mixed together and incubated for 25 min at 24°C. The 
solutions were then added to preplated Neuro-2a cells and incu-
bated for 24 h. After 24 h, the Opti-MEM was removed and re-
placed with growth medium. 50 or 500 nM of filter-sterilized 
nicotine was added after replacing the Opti-MEM with standard 
culture medium (623 nAChRs). For 42 nAChRs, 100 nM 
nicotine was used for 48 h (nicotine was added at the time of 
transfection and then replenished when the media was changed). 
20 µM CI-976 was added with nicotine 24 h before imaging. Cells 
were imaged 48 h after transfection.
Patch-clamp recordings
For patch-clamp electrophysiology, 50,000 Neuro-2a cells were 
plated onto sterilized 12-mm glass coverslips (Deckgläser), placed 
in 35-mm culture dishes, and cultured in a humidified incubator 
(37°C, 95% air, 5% CO2). Recorded cells were visualized with an 
inverted fluorescence microscope (IX71; Olympus) in either bright 
field or fluorescence (eGFP) mode using a high pressure Hg lamp 
(HB-10103AF; Nikon). Electrophysiological signals were recorded 
with an amplifier (Axopatch-1D; Axon Instruments), analogue- 
to-digital converter (Digidata 1440A; Axon Instruments), and soft-
ware (pClamp 10.0; Axon Instruments). Patch pipettes were filled 
with solution containing (mM): 135 K gluconate, 5 KCl, 5 EGTA, 
0.5 CaCl2, 10 HEPES, 2 Mg-ATP, and 0.1 GTP (pH was adjusted to 
7.2 with Tris-base, and osmolarity was adjusted to 280–300 mOsm 
with sucrose). The resistance of patch pipettes was 2–4 MΩ for 
whole-cell recordings. Junction potential was nulled just before 
Furthermore, nicotine self-administration can be blocked 
by the selective antagonism of 6* (*, IUPHAR nomen-
clature, “other subunits may be present”) (Jackson 
et al., 2009) or 4* (Yoshimura et al., 2007) nAChRs. 
From this, it is clear that the nAChRs mediating nico-
tine addiction include those that contain 4, 6, and 2 
subunits (Picciotto et al., 1998; Tapper et al., 2004; Pons 
et al., 2008).
Despite the clarity of 42 nAChR up-regulation, 
there have been conflicting reports of up-regulation, 
down-regulation, or no change in response to chronic 
nicotine for 6* nAChRs (Tumkosit et al., 2006; Perez 
et al., 2008; Walsh et al., 2008). Here, we used mice ex-
pressing 6–enhanced green fluorescence protein 
(eGFP) nAChR subunits to test for in vivo up-regulation 
of 6* nAChRs using concentrations of nicotine com-
parable to those produced by smoking in humans. We 
determined that this up-regulation occurs in all four 
brain areas that robustly express 6* nAChRs: the VTA, 
the substantia nigra pars compacta (SNc), the medial 
habenula, and the superior colliculus.
We then used 6 subunits tagged with supercliptic-
pHluorin (SEP), a pH-sensitive eGFP analogue, expressed 
in neuroblastoma cells to analyze the mechanism of 6* 
nAChR up-regulation. SEP has been used to study vesi-
cle dynamics and synaptic delivery (Miesenböck et al., 
1998; Mani and Ryan, 2009) as well as the trafficking of 
AMPA and GABA receptors (Jacob et al., 2005; Jaskolski 
et al., 2009; Lin et al., 2009; Araki et al., 2010), and we 
have used 4-SEP* to study nAChR trafficking after 
chronic exposure to nicotine (Richards et al., 2011). 
Here, we show that nicotine-induced up-regulation fails 
to occur with inhibition of coat protein complex I 
(COPI)-mediated retrograde traffic from the Golgi to 
the ER (either through the mutation of a putative 
COPI-binding motif [3-KKK] or through the use of 
the COPI inhibitor CI-976). COPI is a protein complex 
that coats vesicles for retrograde transport of proteins 
from the cis end of the Golgi to the ER (Brandizzi and 
Barlowe, 2013). COPI is a heptameric protein com-
plex, and di-lysine–trafficking motifs, including KKxx 
and KxKxx, facilitate protein binding to COPI (Jackson 
et al., 2012; Spang, 2013). Inhibition of COPI-mediated 
trafficking resulted in a decrease of nAChR density in 
the ER and a complementary increase of nAChR den-
sity in the Golgi. Inhibition of COPI had no effect on 
basal insertion of nAChRs in the PM but prevented 
their up-regulation during chronic nicotine treatment. 
Therefore, we propose that the cycling of nAChRs be-
tween the Golgi and ER (via COPI) is necessary for the 
up-regulation of 42 and 623 nAChRs. Our data 
suggest that this may be a common mechanism of 
nAChR up-regulation by nicotine, and that the manipula-
tion of Golgi–ER cycling may lead to novel therapeutic 
strategies for nicotine cessation or neuroprotection 
against Parkinson’s disease.
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Insertion events were quantified using methods similar to those 
published previously (Richards et al., 2011). TIRFM measurements 
to detect membrane insertion events were performed with con-
secutive 200-ms frames. Insertion events were defined as punctate 
regions of fluorescence appearing at the membrane. Insertion 
event data are represented in terms of insertion per 10 µm2 of area 
per minute of observation.
Spectral confocal imaging
Imaging experiments were performed in live Neuro-2a cells at 
37°C in a stage-mounted culture dish incubator (Warner Instru-
ments). For immunostaining, fixed Neuro-2a cells were imaged. A 
C1si laser-scanning confocal microscope (Eclipse; Nikon) equipped 
with a 60× 1.2 NA VC Plan Apo water objective and 32 photomul-
tiplier tubes was used for confocal imaging. Before an imaging 
session, cell culture medium was replaced with phenol red–free 
CO2-independent Leibovitz (L-15) medium (Invitrogen). eGFP 
and mCherry were excited at 488 and 561 nm, respectively. For 
each cell, we focused on a plane containing the most ER exit sites 
(ERES), Golgi bodies, or COPI vesicles, and sequential images 
of eGFP and mCherry fluorescence were obtained. eGFP and 
mCherry fluorescence emission spectra were captured and images 
were unmixed using standard spectra acquired from cells express-
ing eGFP, mCherry, or Alexa Fluor 555 alone. For quantification, 
ERES, Golgi, or COPI regions of interest (ROI) were manually de-
marcated using intensity-based thresholding, and the raw inte-
grated densities were measured for each cell using ImageJ. The 
total Sec24D fluorescence in ERES and the total GalT fluorescence 
per cell were quantified. Error bars for measurements indicate the 
SEM, and p-values are based on a two-tailed t test. The figures show 
a single imaging session that is representative of at least three ses-
sions performed on separate days with similar or identical results.
For direct fluorescence imaging of in vivo 6-GFP* nAChRs, 
images were acquired with the 60× 1.2 NA VC Plan Apo water 
objective at wavelengths between 496 and 561 nm using a 488-nm 
line of an argon laser. Images were collected at 12-bit intensity 
over 512 × 512 pixels, a resolution of 2.5 nm, a 61.3-µm pinhole, 
and a pixel dwell time of 8.4 µs. Autofluorescence was separated 
from GFP fluorescence using techniques that have been published 
previously (Nashmi et al., 2007). Image analysis of cell counts and 
mean intensities were done with ImageJ.
Normalized Förster resonance energy transfer (NFRET)
The general methods for Förster resonance energy transfer from 
sensitized acceptor emission have been described previously 
(Srinivasan et al., 2011, 2012a). For these studies, Neuro-2a cells 
were transfected with 6-mCherry, 2wt, COP-GFP, and 3wt or 
3AAA nAChR subunits. Cells transfected with either 6-mCherry 
or COP-GFP alone were included in all imaging sessions to con-
trol for pixel saturation and spectral bleedthrough. Live cells 
were imaged with a C1si laser-scanning confocal microscope 
(Eclipse; Nikon). During acquisition of images, cells were focused 
on a plane where the COP-GFP fluorescence most resembled 
the pattern for the endogenous COPI staining (see Fig. 4 E). GFP 
and mCherry images were acquired with 488- and 561-nm laser 
lines, and images were linearly unmixed by using reference spec-
tra. Reference spectra were acquired from Neuro-2a cells trans-
fected with 6-mCherry or COP-GFP during the same imaging 
session. After linear unmixing, NFRET was calculated using the 
PixFRET ImageJ plug-in as described previously (Moss et al., 
2009; Srinivasan et al., 2011, 2012a).
Plasmid constructs
Mouse 6 with a C-terminal fusion of an SEP tag was constructed 
by PCR amplification using the forward primer 5-CATGGTTGG-
CTGGTATGATCAGTAAAGGAGAAGAACTT-3 and the reverse 
primer 5-ATGGATGAACTATACAAATAGGGAATAGCGGCACCT-3, 
forming a gigaseal. All recordings were done at 24°C. Data were 
sampled at 10 kHz and filtered at 2 kHz for whole-cell recordings. 
Acetylcholine was dissolved in extracellular solution containing 
(mM) 140 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, and 10 glu-
cose (320 mOsm, pH set to 7.3 with Tris-base), and were puffed 
(0.3 s, 20 psi) onto voltage-clamped Neuro-2a cells (holding po-
tential [VH] of 50 mV). To avoid receptor desensitization by re-
petitive ACh application, we applied ACh at 3-min intervals and 
continually perfused the recording chamber with extracellular 
solution. For concentration response studies, we used a rapid su-
perfusion system with 500-ms puffs of agonist (Octaflow II; ALA 
Scientific Instruments).
Immunostaining and antibodies
For immunostaining, cultured Neuro-2a cells were fixed with 4% 
paraformaldehyde (15 min), permeabilized in 0.01% Triton X-100 
(5 min), and blocked with 10% goat serum (30 min). After two 
PBS washes, the appropriate primary antibody (1:500) in 1% goat 
serum was applied for 1 h at 24°C. Cells were washed three times 
with PBS and incubated with 1% goat serum containing second-
ary antibody (1:2,000) for 1 h at 24°C. Cells were washed three 
times with PBS and imaged immediately. Immunostaining used 
-COP rabbit polyclonal antibody as the primary (antibody 2899; 
Abcam) and Alexa Fluor 555–labeled secondary (goat anti–rabbit; 
Invitrogen) antibodies.
Midbrain 6-GFP neurons existed in a high enough density to 
be imaged without staining (direct/inherent fluorescence). Im-
munohistochemical techniques were required for observing 6-
GFP fluorescence in other regions of the mouse brain. 20-µm 
brain sections on slides were rinsed twice for 10 min with PBS and 
then permeabilized with 0.5% Triton X-100 in PBS for 1 h. Brain 
sections were then blocked with 4% goat serum (Jackson Immuno-
Research Laboratories, Inc.) in PBS for 45 min. The primary 
antibody was diluted in 4% goat serum in PBS and incubated 
overnight at 24°C. Brain sections were then washed three times 
for 15 min with PBS, and the secondary antibody was diluted in 
4% goat serum in PBS and incubated for 1 h at 24°C. Finally, 
brain sections were washed three times for 15 min with PBS and 
mounted with Vectashield.
Total internal reflection fluorescence microscopy (TIRFM)
Cultured Neuro-2a cells were imaged live at 37°C in a stage-
mounted culture dish incubator (Warner Instruments) using 
methods similar to TIRFM assays in cultured cortical neurons 
(Richards et al., 2011). TIRFM enables the visualization of fluo-
rescently labeled intracellular molecules within 250 nm of the 
cell-coverslip interface. TIRFM images were obtained using an in-
verted fluorescence microscope (IX81; Olympus) equipped with 
a 100× 1.45 NA oil objective (PlanApo; Olympus) and a stepper 
motor (Thorlabs) to control the position of the fiber optic and 
TIRFM evanescent field illumination. Just before imaging, growth 
medium was exchanged for extracellular solution (150 mM NaCl, 
4 mM KCl, 10 mM HEPES, 2 mM MgCl2, 2 mM CaCl2, and 10 mM 
glucose), adjusted to the appropriate pH (5.4 or 7.4). SEP was 
excited at 488 nm with an air-cooled argon laser (IMA101040ALS; 
Melles Griot). Images were captured with a back-illuminated 
EMCCD camera (iXon DU-897; Andor). We acidified the imaging 
dish by perfusing the bath, normally at pH 7.4, with an otherwise 
identical solution adjusted to pH 5.4. The PM integrated density 
(PMID) was determined by taking an initial TIRFM image of each 
cell at pH 7.4, followed by acidification of the solution and a sub-
sequent low pH image (pH 5.4). Low pH images were used to 
demarcate ER-localized nAChRs, which were subtracted from the 
total footprint to determine the PMID of nAChRs. The figures 
show a single imaging session that is representative of at least 
three sessions performed on separate days with similar or identi-
cal results.
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R E S U L T S
In vivo up-regulation of 6* nAChRs with chronic nicotine
We used a mouse line containing GFP-labeled 6* 
nAChRs to study the up-regulation of 6* nAChRs 
(Mackey et al., 2012). 6-GFP nAChR subunits assemble 
appropriately with other nonlabeled nAChR subunits, 
traffic properly, and function in electrophysiological as-
says in a manner comparable to that of WT nAChRs 
(Mackey et al., 2012).
Direct fluorescence of 6-GFP* nAChRs was apparent 
in the VTA and SNc of saline- or nicotine-treated mice 
(Fig. 1 A). The fluorescence intensity of 6-GFP* 
nAChRs in the VTA and SNc of mice administered nico-
tine at 2 mg/kg/h for 10 d was increased twofold com-
pared with that of saline-treated mice (P < 0.005; Fig. 1, 
B1 and C1). In addition, we used cumulative percentage 
plots to compare saline and nicotine treatments (Fig. 1, 
B2 and C2). Cumulative percentage plots are similar to a 
cumulative frequency analysis and allow us to compare 
the full range of 6-GFP fluorescence intensities between 
saline and nicotine treatments. In all four brain regions, 
we can see that the percentage of low, mid, and high 
6-GFP fluorescence intensities are shifted to the right 
which overlap with sequences within the C-terminal end of the 
6-coding sequence. This PCR product was then cloned directly into 
the vector containing the 6 gene using Pfu-Turbo polymerase. 
The mouse 23 nAChR subunit was constructed by PCR amplifica-
tion using the forward primer 5-ATGGCCCGGTGCTCC AACTC-3 
and the reverse primer 5-CCTGCCCTCAGACTGT GGTG-3. The 
mouse 32 nAChR subunit was constructed by PCR amplification 
using the forward primer 5-ATGACAGGC TTCCTACGGGT-3 and 
the reverse primer 5-ACGGTCCTG GTGTTCTACCT-3. Mouse 
3AAA (the KKK mutated to AAA) and the 23[AAA] were constructed 
by PCR amplification using the forward primer 5-AAATTTCCAG-
GGGCTGCAGCCCAGACTC CTA CC-3 and the reverse primer 
5-CCCCCTCACGGTTCCCTTACTCTCCGT-3.
Online supplemental material
Fig. S1 illustrates that the presence of 3 subunits increased the 
PMID of 64 nAChRs but is not required for the up-regulation 
of 64* nAChRs. Fig. S2 presents a schematic of the various chime-
ras and mutant nAChR subunits that were used in this paper. Fig. S3 
shows the electrophysiological characterization of 623WT and 
623AAA nAChRs after treatment with nicotine. Here, we show 
that functional up-regulation accompanies the increase in PMID 
for 623WT nAChRs when treated with nicotine, but there is no 
functional up-regulation with 623AAA nAChRs. Fig. S4 illustrates 
that treatment with CI-976 produces an increase of nAChRs in the 
Golgi but does not increase export from the ER. Fig. S5 shows 
that CI-976 treatment does not affect basal PMID of nAChRs. The 
online supplemental material is available at http://www.jgp.org/ 
cgi/content/full/jgp.201311102/DC1.
Figure 1. Chronic nicotine up-
regulates 6-GFP* nAChRs in 
four brain regions. (A) Direct 
fluorescence imaging of SNc and 
VTA in mice expressing 6-GFP 
subunits after treatment with 
saline or nicotine (2 mg/kg/h, 
10 d). (D1 and E1) Immunohisto-
chemical imaging of medial ha-
benula and superior colliculus 
in mice expressing 6-GFP sub-
units after treatment with saline 
or nicotine. For all images, mon-
tages were compiled from indi-
vidual 60× images. (A and E1) 
Bars, 100 µm. (D1) Bars, 20 µm. 
(B1 and C1) Quantification of 6-
GFP intensities in SNc and VTA 
of saline- and nicotine-treated 
mice (n = 6 mice). (D2 and E2) 
Quantification of 6-GFP inten-
sities in medial habenula and 
superior colliculus of saline- and 
nictotine-treated mice (n = 6 
mice). (D3 and E3) Quantifica-
tion of 6-GFP immunofluores-
cence of medial habenula and 
superior colliculus neurons in 
saline- and nicotine-treated mice 
(n = 4–5 mice). (B2, C2, D3, and 
E3) Cumulative percentage plots 
show changes in 6-GFP fluores-
cence in all brain regions with 
chronic nicotine. ***, P < 0.005; 
*, P < 0.05.
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(Asokan and Cho, 2002; Jaskolski et al., 2009). When ex-
posed to a neutral buffer (pH 7.4) both ER- and 
PM-resident nAChRs are fluorescent. Upon perfusing 
an acidic buffer (pH 5.4), PM-resident nAChR fluores-
cence is quenched, whereas the ER component remains 
fluorescent. Thus, SEP allows the differentiation of re-
ceptors within the ER from those in the PM. As in a 
previous study using SEP tagged to 4 nAChRs (Rich-
ards et al., 2011), we fused SEP to the C terminus of 6 
subunits so that it was positioned on the luminal side of 
organelles in the secretory pathway.
nAChRs with eGFP subunits have little or no func-
tional difference (i.e., peak current amplitude, decay 
time) from WT subunits (Drenan et al., 2008; Richards 
et al., 2011; Srinivasan et al., 2011, 2012b; Xiao et al., 
2011) and, indeed, we found no detectable functional 
difference between 6-SEP23 nAChRs and 6-
eGFP23 nAChRs (Fig. 3). Inclusion of the 3 sub-
unit increased ACh-induced peak currents by threefold 
compared with those obtained with 6-eGFP2 
nAChRs (Fig. 3 B; P < 0.05). Inclusion of the 3 sub-
unit also reduced the concentration of ACh at which 
we observed maximal peak amplitude from 300 µM 
(6-eGFP2) to 3 µM (6-eGFP23) (Fig. 3). Con-
centration–response studies of ACh and ()-nicotine 
on 6-eGFP23 nAChRs yielded EC50 values of 0.31 ± 
0.10 µM and 0.12 ± 0.08 µM, respectively (Fig. 3, C and D), 
which agree with those obtained with linked con-
catamers containing (62)23 nAChRs (Kuryatov and 
Lindstrom, 2011).
(higher intensity) after chronic nicotine treatment (Fig. 1, 
B2 and C2). Nicotine at 0.4 mg/kg/h also increased 6-
GFP fluorescence intensity in VTA (60.8 ± 10.9% increase) 
and SNc (70.0 ± 1.4% increase) neurons (P < 0.05 com-
pared with saline; Fig. 2). Similar to 2 mg/kg/h nicotine 
treatments, the 0.4-mg/kg/h nicotine treatment shifted 
the full range of 6-GFP fluorescence intensities to the 
right in cumulative percentage plots (Fig. 2, D1 and D2).
2 mg/kg/h nicotine also increased the fluorescence 
intensity of medial habenula and superior colliculus 6-
GFP* nAChRs (81% [P < 0.005] and 68% [P < 0.05], 
respectively; Fig. 1, D and E). In cumulative percentage 
plots, we can also see that the full range of 6-GFP fluo-
rescence intensities is shifted to the left after chronic 
nicotine treatment (Fig. 1, D1 and D2).
6-SEP* nAChRs assemble functional receptors, and 3 
subunits increase 6* nAChR function
To perform a systematic study on 6* nAChR up-
regulation, we used an expression system, Neuro-2a 
cells, which has been optimized to avoid many artifacts 
of “overexpressing” PM proteins. The appearance of 
functional PM proteins in this system is linear and un-
saturated as a function of parameters such as level of 
transfected cDNAs, trafficking machinery, oligomeriza-
tion, and anchoring (Moss et al., 2009).
SEP undergoes 488-nm excitation at neutral pH 
(7.4) but not under acidic conditions (Richards et al., 
2011). 6-SEP* nAChRs in the Golgi and secretory vesicles 
(6.7 and <6.5 pH, respectively) are not fluorescent 
Figure 2. Low concentrations of nicotine (0.4 mg/kg/h) up-regulate 6-GFP* nAChRs in midbrain neurons. (A and B) Direct fluo-
r escence imaging of VTA and SNc neurons in mice expressing 6-GFP subunits after treatment with saline or nicotine (0.4 mg/kg/h, 
10 d). Bars, 100 µm. (C1 and C2) Quantification of 6-GFP intensities of neurons in saline- or nicotine-treated mice (n = 4 mice). 
(D1 and D2) Cumulative percentage plots show changes in 6-GFP fluorescence in the SNc and VTA with chronic nicotine (0.4 mg/
kg/h; n = 4 mice). *, P < 0.05.
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As reported previously (Tumkosit et al., 2006), 623 
nAChRs had a higher density on the PM than 62 
nAChRs; the PMID of 623 nAChRs was three times 
that of 62 nAChRs (P < 0.0001; Fig. 4 B). We also 
found a 1.5-fold increase in the PMID of 643 
nAChRs compared with that of 6-SEP4* nAChRs 
(Fig. S1). We found that, when expressed in Neuro-2a 
Incorporation of 3 subunits increases the density of 6* 
nAChRs at the PM
We used TIRFM and 6-SEP* nAChRs transfected in 
Neuro-2A cells to quantify the density of receptors in 
the peripheral ER versus the PM. Fig. 4 A shows TIRFM 
images of Neuro-2a cells expressing 6-SEP2 or 6-
SEP23 nAChRs at neutral (7.4) and acidic (5.4) pH. 
Figure 3. The 6-SEP nAChRs are functional. Representative whole-cell ACh-induced currents of (A1) 6-SEP23 nAChRs (3 µM 
ACh). (A2) 6-eGFP23 nAChRs (3 µM ACh) and (A3) 6-eGFP2 nAChRs (300 µM ACh). (B) Comparison of whole-cell ACh-induced 
current amplitudes of 6-SEP23, 6-eGFP23, and 6-eGFP2 nAChRs (n = 7–11). (C) Concentration–response of ACh on 6-
eGFP23 nAChRs (n = 15). (D) Concentration-response of ()-nicotine on -eGFP23 nAChRs (n = 14). *, P < 0.05.
Figure 4. The 3 subunit in-
creases the density of 6* 
nAChRs at the PM and is nec-
essary for the nicotine-induced 
up-regulation of 62* nAChRs. 
(A, C, and E) Representative 
TIRFM images of Neuro-2a cells 
transfected with 6-SEP and a 
combination of 2 with or with-
out 3 nAChR subunits at basic 
(pH 7.4) and acidic (pH 5.4) 
conditions. Nicotine was added 
at listed concentrations 24 h 
before imaging. (B, D, and F) 
PMID for 6-SEP* nAChRs. 
Bars, 10 µm (n = 19–23). Data are 
mean values ± SEM. n.s., not sig-
nificant; ***, P < 0.0001.
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nAChRs (Fig. 5, C and D). These data correlated with the 
observed nicotine-induced changes of PM intensities 
for 6-SEP23 and 6-SEP2 nAChRs. Specifically, we 
note a similarity between the increase in PMID and rate 
of insertion of 6-SEP23 nAChRs (both are an ap-
proximate threefold increase) (Fig. 5, C and D). This sug-
gests that the up-regulation of 623 nAChRs is caused 
primarily by increased insertion into the PM, with no major 
contribution from decreased internalization of receptors 
from the PM (Lomazzo et al., 2011).
Despite the different PMIDs between 6-SEP23 
and 6-SEP2 nAChRs, they showed the same rate of 
insertion under basal conditions (12 ins/min). There-
fore, the difference in the PM density of 6-SEP23 
and 6-SEP2 nAChRs may be caused by differential 
rates of internalization or stability of these nAChR sub-
types at the PM, suggesting that the 3 nAChR subunit 
may provide a stabilizing effect.
A KKK motif within the 3 M3–M4 loop governs the 
up-regulation of 623 nAChRs
Our data suggest that 3 subunits markedly influence 
the trafficking and dynamics of 62* nAChRs. We 
next sought to identify specific motifs within 3 subunits 
that may play a role in the trafficking and dynamics of 
62* nAChRs.
We engineered a series of chimeras: (a) a chimera 
with a 3 M3–M4 loop replacing the 2 M3–M4 loop in 
a 2 subunit (23) and (b) a chimera with a 2 M3–M4 
loop replacing the 3 M3–M4 loop in a 3 subunit (32) 
(see Fig. S2). 6-SEP223, 6-SEP23, 6-SEP232, 
and 6-SEP32 nAChRs exhibited typical TIRFM foot-
prints and PM-ER fluorescence that were similar to 6-
SEP2* nAChRs (Fig. 6). 6-SEP223 and 6-SEP23 
cells, 6-SEP3 nAChRs resided almost entirely in the 
ER (94.5 ± 2.2% ER localization; not depicted). Collec-
tively, these data show that the 3 subunits, combined 
with 2 or 4 nAChR subunits, increase the density of 
6* nAChRs on the PM.
Confirmation that 3 subunits enhance nicotine-induced 
up-regulation of 62* nAChRs
We next assessed the effect of chronic nicotine on 62* 
nAChRs. We examined 6* nAChRs exposed to 50 or 
500 nM nicotine for 24 h. 50- and 500-nM nicotine con-
centrations, respectively, mimic the steady-state and 
peak concentrations of nicotine found in the brains of 
smokers (Marks et al., 2004). 50 nM nicotine also equals 
the plasma concentration produced by 14–21-mg nico-
tine patches (Schnoll et al., 2013). We observed a signifi-
cant (P < 0.0001) increase in the PMID of 6-SEP23 
nAChRs after treatment with 50 nM nicotine, but a sig-
nificant (P < 0.0001) decrease in PMID after 500-nM 
nicotine treatment (Fig. 4, C and D). 6-SEP2 nAChRs 
showed no change in PMID after 50-nM nicotine treat-
ment and a decrease in PMID after 500-nM nicotine 
treatment (Fig. 4, E and F). 50 or 500 nM nicotine in-
duced a greater than threefold increase in 6-SEP4* 
nAChRs PMIDs in the presence or absence of the 3 
subunit (Fig. S1).
Dynamic visualization of SEP nAChRs enables us to 
see when nAChRs arrive at the PM, as they appear as a 
region of punctate fluorescence (Richards et al., 2011; 
Fig. 5, A and B1–3). We quantified the frequency of these 
vesicular insertion events at the PM (Fig. 5). After expo-
sure to 50 nM nicotine, we observed a threefold increase 
in the insertion events of 6-SEP23 nAChRs (P < 0.05) 
and no change in the insertion events of 6-SEP2 
Figure 5. Visualization of membrane insertion events. 
(A) TIRFM image of a Neuro-2a cell transfected with 
6-SEP23 nAChRs and excited with a 488-nm laser. 
Images were taken with a frame rate of 200 ms. (B1) 
Frame directly preceding an insertion event at the PM. 
(B2) Frame showing the insertion and (B3) the frame 
directly after the observation of the insertion event. 
The white circle marks the location of the insertion. 
(C and D) Frequency of insertion events for 6-SEP2* 
nAChRs without or with nicotine treatment (50 nM, 
24 h) calculated as insertion events per minute (n = 4). 
Bars, 10 µm. Data are mean values ± SEM. n.s., not sig-
nificant; *, P < 0.05.
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nAChRs (Fig. S3). 6-eGFP23 or 6-eGFP23AAA 
nAChRs did not show a difference in ACh-induced cur-
rents under basal conditions. These results correlated with 
the observed PMIDs of 6-SEP23 and 6-SEP23AAA 
nAChRs (Fig. 6).
Nicotine up-regulates nAChRs by binding to and chap-
eroning ER-localized receptors, which are then trafficked 
to the PM (Srinivasan et al., 2011). The formation of ad-
ditional ERES with nicotine is a direct indicator of an 
event immediately after the nAChR chaperoning pro cess 
(Srinivasan et al., 2011). To assess the effect of nicotine 
on 623AAA nAChR chaperoning, we quantified the 
formation of condensed ERES (Fig. 7, A and B). Neuro-
2a cells were cotransfected with either 6-eGFP23 
or 6-eGFP23AAA nAChRs and Sec24D-mCherry 
(a marker for active ERES) (Srinivasan et al., 2011). 50 nM 
nicotine caused a significant (P < 0.005) threefold in-
crease of ERES in 6-eGFP23 nAChRs but no change 
in ERES with 6-eGFP23AAA nAChRs (Fig. 7 B).
The 3 KKK motif inhibits up-regulation by preventing 
retrograde Golgi to ER nAChR transport
We observed a decrease in the ER density of 3-AAA 
nAChRs compared with WT nAChRs (Fig. 6, C and D) 
and hypothesized that loss of the KKK (COPI-binding 
motif) disrupted trafficking between the Golgi and ER. 
To test this hypothesis, we studied how WT and 3-AAA 
nAChRs localized within the Golgi. Fig. 7 (C and D) shows 
colocalization of 6-eGFP23 and 6-eGFP23AAA 
nAChRs with the Golgi marker GalT-mCherry. 3AAA 
subunits caused a significant increase in the Pearson 
nAChRs up-regulated with 50 nM nicotine, whereas 6-
SEP32 and 6-SEP232 nAChRs showed either no 
change or a decrease in the PMID with 50 nM nicotine, 
suggesting that the 3 subunit M3–M4 domain specifi-
cally regulates nicotine-induced up-regulation but may 
not control the basal trafficking of 6* nAChRs (Fig. 6, 
A2 and B2).
Unique among nAChR subunits, the 3 nAChR sub-
unit possesses a KKK motif within its M3–M4 loop. Di-
lysine trafficking motifs, including KKxx and KxKxx, 
facilitate protein binding to COPI, a component of the 
Golgi–ER retrograde transport machinery (Jackson 
et al., 2012). Although these motifs typically occur at 
cytoplasmic C termini, the KKK found in the 3 subunit 
satisfies both of these consensus motifs. Thus, we hypoth-
esized that the KKK may act as a COPI recognition site. 
We mutated the 381KKK383 motif in the 3 M3–M4 loop 
to 381AAA383 to create 23[AAA] and 3AAA nAChR sub-
units. Mutant nAChRs exhibited a typical TIRFM foot-
print and showed comparable overall nAChR expression 
to WT receptors (Fig. 6, C and D). We observed a sig-
nificant decrease in the number of ER resident 6-
SEP223[AAA] and 6-SEP23AAA nAChRs (Fig. 6, C1 
and D1). In addition, the 6-SEP223[AAA] and 6-
SEP23AAA nAChRs did not increase the PMID when 
treated with 50 nM nicotine (Fig. 5, C and D), suggest-
ing that the KKK motif was essential for the nicotine-
induced up-regulation of 6-SEP2* nAChRs. Similarly, 
we found a 44% increase in peak ACh-induced currents 
for 6-eGFP23 nAChRs after treatment with 50 nM 
nicotine (24 h) but no increase for 6-eGFP23AAA 
Figure 6. The 3 KKK motif participates in nAChR up-regulation. (A1, B1, C1, and D1) Representative TIRFM images of Neuro-2a cells 
transfected with 6-SEP and cotransfected with combinations of 2, 23, 32, 23[AAA], and 3AAA subunits. 50 nM nicotine was added 
24 h after transfection. Bars, 10 µm. (A2, B2, C2, and D2) PMID for nAChRs (n = 11–27). ***, P < 0.0001 (ANOVA).
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Upon treatment with 50 nM nicotine, we observed a 
twofold increase in the 6-eGFP23 nAChR density in 
COPI vesicles when compared with non-nicotine–treated 
conditions. In contrast, there was no increase in 6-
eGFP23AAA nAChRs (Fig. 7 F1). This suggests that 
after chronic nicotine treatment, an increase of 6* 
nAChRs in COPI vesicles accompanies the up-regula-
tion observed on the PM. Collectively, these data show 
that a defect in the recognition between COPI vesicles 
and 6-eGFP23AAA nAChRs results in decreased ret-
rograde movement of these nAChRs back into the ER.
The COPI inhibitor CI-976 blocks up-regulation but not 
basal trafficking of 623 and 42 nAChRs
Our data suggest that Golgi–ER cycling of 623 
nAChRs is necessary for up-regulation during chronic 
exposure to nicotine. Next, we investigated whether this 
also applies to other subtypes. For these experiments, 
we used CI-976, which inhibits COPI-mediated retro-
grade trafficking at concentrations ≥20 µM (Yang et al., 
2005, 2011). Inhibition of COPII vesicle budding occurs 
at a somewhat higher concentration (50 µM) (Brown 
et al., 2008).
correlation coefficient for 6-eGFP and GalT-mCherry 
colocalization (Fig. 7 D1; P < 0.0001) and a significant 
(P < 0.01) increase in the 6-eGFP23AAA nAChR den-
sity when compared with 6-eGFP23 nAChRs, within 
the Golgi (Fig. 7 D2). Therefore, the removal of the 
KKK motif increased the density of 623 nAChRs in 
the Golgi compartment.
To determine whether COPI Golgi–ER trafficking is 
deficient, we assessed colocalization by immunostaining 
for endogenous COPI in Neuro-2a cells transfected 
with 6-eGFP23 and 6-eGFP23AAA nAChRs (Fig. 7, 
E, F1, and F2). We found that 6-eGFP23AAA nAChRs 
exhibited a significant, twofold decrease in density in 
COPI vesicles when compared with 6-eGFP23 
nAChRs (Fig. 7 F1; P < 0.01). This was accompanied by 
a significant decrease in the pixel-based Pearson corre-
lation coefficient among WT and 3-AAA nAChRs (P < 
0.0001; Fig. 7 F2). Despite this decrease, we observed no 
difference in the 6-eGFP* whole-cell fluorescence 
intensity between 6-eGFP23 nAChRs and 6-
eGFP23AAA nAChRs (20.2 ± 3.1 and 18.3 ± 4.8 RFUs 
[millions], respectively). Thus, the potential contribution 
from degradation is unlikely.
Figure 7. 3-AAA nAChRs show 
increased density in Golgi despite 
no change in ER export. Confocal 
image of 6-eGFP23 and Sec24D-
mCherry (A), 6-eGFP23 with 
Golgi marker GalT-mCherry (C), 
and 6-eGFP23 nAChRs stained 
for endogenous -COP (E). Quanti-
fication of: Sec24D fluorescence in 
ERES per cell for 6-eGFP23WT 
and 6-eGFP23AAA nAChRs (B) 
(n = 21–31); Pearson correlation be-
tween 6-eGFP* and GalT-mCherry 
fluorescence for 6-eGFP23WT 
and 6-eGFP23AAA nAChRs (D1) 
(n = 30–35); 6-eGFP* intensity in 
Golgi for 6-eGFP23WT and 6-
eGFP23AAA nAChRs (D2) (n = 30–
35); 6-eGFP fluorescence in COPI 
vesicles for 6-eGFP23WT and 
6-eGFP23AAA nAChRs (F1) (n = 
23–25); and Pearson correlation 
for the colocalization of 6-eGFP* 
fluorescence with COPI fluores-
cence in 6-eGFP23WT and 6-
eGFP23AAA nAChRs (F2) (n = 
23–24). Bars, 5 µm. *, P < 0.01; **, P < 
0.005; ***, P < 0.0001 (ANOVA).
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either 44 or 42-DM nAChRs, it would indicate an 
inhibitory effect on COPI-mediated anterograde traffic. 
We observed no change in the PMID of 44 or 
42-DM nAChRs after CI-976 treatment (Fig. S5). We 
also note (again) that COPI did not change the level of 
basal ERES (Fig. S4 A), arguing against the idea that 
exit from the ER is affected by CI-976. Collectively, these 
data suggest that CI-976 effects are exerted on COPI’s 
retrograde pathway only.
623 nAChRs treated with CI-976 produced simi-
lar trends compared to 623AAA nAChRs (compare 
Figs. 6 D2 to 8 B1). As usual, 50 nM nicotine treatment 
produced a significant (P < 0.005) increase in the PMID 
of 6-SEP23 nAChRs (Fig. 8 B1). Treatment with 
20 µM CI-976 alone did not differ from the basal condi-
tions seen in 6-SEP23 nAChRs (no change in PMID), 
but when cells were coexposed to CI-976 and nicotine, 
up-regulation of 6-SEP23 nAChRs was blocked 
(Fig. 8 B1). Previous analyses show that 100 nM nicotine 
is an appropriate concentration for the study of 4-
SEP2 nAChR up-regulation (Richards et al., 2011; 
Srinivasan et al., 2011). We observed a significant (P < 
0.05) increase in the 4-SEP2 nAChR PMID with 
First, we assessed the effects of 20 µM CI-976 on ERES 
(Fig. S4 A). CI-976 did not affect the basal number of 
ERES in 6-GFP23 nAChRs but did prevent the in-
crease in ERES with chronic nicotine treatment (50 nM). 
This is the same trend that was observed with 6-
GFP23AAA nAChRs (see Fig. 6 D2). With CI-976 treat-
ment, we also noted a significant (P < 0.005) increase in 
the 6-GFP density in the Golgi (Fig. S4 B) and a signifi-
cant (P < 0.05) increase in the Pearson correlation coef-
ficient for colocalization of 6-eGFP and GalT-mCherry 
(Fig. S4 C). These data mimic the results seen with 6-
GFP23AAA nAChRs (Fig. 7) and suggest that CI-976 
can be used to study the inhibition of Golgi–ER cycling 
in nAChRs.
COPI may play a role in anterograde transport in ad-
dition to its role in retrograde transport (Yang et al., 
2011). We conducted experiments to determine whether 
the concentration of CI-976 we used inhibited COPI-
mediated anterograde traffic of nAChRs. We studied 
44 and 42enhanced-ER-export (also called 42-DM 
nAChRs), which both have a high rate of passage from 
ER to the PM (Richards et al., 2011; Srinivasan et al., 
2011). We reasoned that if CI-976 reduced the PMID of 
Figure 8. Blocking Golgi–ER cycling prevents 
up-regulation of nAChRs. (A) Representative 
TIRFM images of 4-SEP2 (right) or 6-
SEP23 (left) nAChR subunits. Nicotine (50 nM 
6-SEP23 nAChRs or 100 nM 4-SEP2 
nAChRs) and/or 20 µM CI-796 were added 24 h 
before imaging. Bars, 10 µm. Quantification of 
PMID for 6-SEP23 nAChRs (B1) or 4-SEP2 
nAChRs (B2) in Neuro-2a cells with drug treat-
ments: no drug, nicotine, CI-976, or combined (n = 
17–23). *, P < 0.05; ***, P < 0.0001 (ANOVA).
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NFRET of the cell’s nonzero FRET pixels, the NFRET 
among cells was significantly decreased in the presence 
of nAChRs with the 3-AAA mutation or treatment with 
CI-976 (Fig. 9 C). In addition to NFRET, we used COP-
GFP fluorescence to demarcate ROI for COPI vesicles, 
and then examined the density of 6* nAChRs in the 
COPI ROI (as in Fig. 7 F1). 6-eGFP23AAA nAChRs (no 
drug) and WT 6-eGFP23 nAChRs (treated with CI-
976) exhibited a significant decrease in their density 
within COPI vesicles (Fig. 9 D; P < 0.005). This was ac-
companied by a significant decrease in the pixel-based 
Pearson correlation coefficient (Fig. 9 E). Collectively, 
these results demonstrate that disruption of the KKK 
motif or inhibition of COPI destabilizes the interaction 
between COPI and 623 nAChRs.
D I S C U S S I O N
6* nAChRs up-regulate after chronic nicotine treatment
This paper documents the in vivo up-regulation of 6* 
nAChR protein at a sustained nicotine concentration 
comparable to that in human smokers. We found that 
up-regulation occurs in the four major brain regions 
that express 6-GFP nAChRs: VTA, SNc, medial haben-
ula, and superior colliculus (see Figs. 1 and 2).
The 6 and 3 nAChR subunits have nearly identical 
expression patterns in the brain, as reported by analysis 
100 nM nicotine and, similar to our observations in 6-
SEP23 nAChRs, treatment of 4-SEP2 nAChRs with 
CI-976 alone did not differ from basal conditions (no 
change in PMID) (Fig. 8 B2). When both CI-976 and 
nicotine were present with 4-SEP2 nAChRs, up-regu-
lation was prevented (Fig. 8 B2). These results suggest 
that a COPI-dependent process, related to Golgi–ER cy-
cling, is necessary for the nicotine-induced up-regula-
tion of 42 as well as 623 nAChRs.
NFRET measurements of the 623–COP interaction
We asked whether nAChRs and COPI display NFRET. 
Neuro-2a cells were transfected with 6-mCherry, 2, 
and 3 (WT and 3-AAA) nAChR subunits along with 
COP-eGFP (Fig. 9 A). Fig. 9 A shows that NFRET 
between 6-mCherry and COP-eGFP exhibited pat-
terns similar to endogenous COP staining (see Fig. 7 E). 
Evidently, 6-mCherry and COP-eGFP colocalize 
within 100 Å.
We asked whether the 3-AAA mutation or CI-976 can 
inhibit the interaction between 623 and COP. 
nAChRs with the 3-AAA mutation consistently shifted 
pixel-based NFRET amplitude distributions to lower val-
ues (Fig. 9, A–C). Treatment with CI-976 also consistently 
shifted pixel-based NFRET amplitude distributions to 
lower values (Fig. 9, A–C). Similarly, when we assigned an 
NFRET value to each cell by calculating the average 
Figure 9. 3-AAA nAChRs and CI-976 
treatment decrease interaction be-
tween 6 and COPI. NFRET measure-
ments were made using 6-mCherry 
and COP-eGFP transfected in Neuro-
2a cells (along with 2 and 3wt or 
3AAA subunits). (A) Representative 
NFRET images between 6-mCherry 
and COP-eGFP in Neuro-2a cells. 
Bars, 10 µm. (B) Summed histograms 
of pixel-based NFRET measurements, 
representative of four independent 
NFRET assays (n = 20 cells). C–E show 
analysis of the same group of cells (n = 
28 cells). (C) Another of the four ex-
periments. Scatter-box plot for the 
mean NFRET values of individual 
cells. The larger black diamond () 
in the box plot represents the cell-
based mean of each condition. (D) 6-
eGFP fluorescence in COPI vesicles 
for 6-eGFP23AAA nAChRs and 6-
eGFP23WT nAChRs (without and 
with 20 µM CI-976). (E) Pearson cor-
relation for the colocalization of 6-
eGFP* fluorescence with COP-GFP 
fluorescence (n = 28 cells). *, P < 0.05; 
**, P < 0.01; ***, P < 0.005 (ANOVA).
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in the contribution of 6* nAChRs, as identified by bind-
ing or dopamine release assays (Lai et al., 2005; Perry 
et al., 2007; Exley et al., 2013). Several factors may contrib-
ute to these disparate findings. First, the up-regulation 
of 6* nAChRs we observed was in midbrain (VTA and 
SNc) dopaminergic neurons, whereas the studies show-
ing a decrease in 6* nAChR contribution were com-
pleted in the striatal regions. We have confirmed 
previously that 6-GFP* nAChRs in the VTA and SNc are 
localized exclusively in dopaminergic neurons (Mackey 
et al., 2012). The difference in striatal (down-regulation) 
and midbrain (up-regulation) may be explained by a 
different population of nAChRs (64*, 6[non4]*, 
63*, and/or 6[non3]*). Perez et al. (2008) have 
shown that although 6(non4)* nAChRs up-regulate, 
64* nAChRs down-regulate. We, along with others 
(Tumkosit et al., 2006), have shown that 6* nAChRs 
may require the 3 subunit to up-regulate. Therefore, 
the population of nAChRs residing in the somata of 
midbrain dopaminergic neurons may be composed of 
of mRNA and autoradiography (Le Novère et al., 1996; 
Azam et al., 2002; Baddick and Marks, 2011). In heter-
ologous systems, 623 nAChRs show better function 
(higher density on the PM, larger peak current re-
sponse) than 62. Therefore, it is appropriate to study 
effects of chronic nicotine on 62* nAChRs in the 
context of coexpressed 3 subunits. We found that, at 
concentrations mimicking the steady-state levels found 
in human smokers and during nicotine replacement 
therapy (50 nM nicotine), 6-SEP23 nAChRs up-reg-
ulate whereas 6-SEP2 nAChRs failed to up-regulate. 
The 3 subunit thus appears necessary for the up-regu-
lation of 6-SEP2* nAChRs. This agrees well with 
Tumkosit et al. (2006), who showed that 3 nAChR 
subunits promote nicotine-induced up-regulation of 
6* nAChRs.
Our observations of 6* up-regulation agree with 
some previously published work (Parker et al., 2004; 
Perez et al., 2008; Walsh et al., 2008). Other studies 
found that chronic nicotine treatment leads to a decrease 
Figure 10. A schematic representation of 
selective pharmacological chaperoning of 
nAChRs in response to chronic nicotine. 
(A) Nicotine interconverts within milliseconds 
between the protonated membrane-imper-
meant form and the neutral membrane-per-
meant form. The latter enters cells and enters 
the ER (red arrow). Here, the charged form 
pharmacologically chaperones nAChRs so 
that increased numbers exit toward the Golgi 
via the COPII pathway, eventually resulting 
in receptor up-regulation at the PM. Thus, 
pharmacological chaperoning by nicotine is 
thought to underlie the process of nAChR 
up-regulation by chronic nicotine. (B) This 
study finds that nicotine-mediated up-regu-
lation also depends on the COPI machinery 
involved in ER to Golgi and Golgi to ER trans-
port of nAChRs. One possible explanation 
for the COPI dependence is that nicotine 
enters additional organelles and binds more 
extensively than previously thought within 
the early exocytic pathway, shown by the ad-
ditional red arrows leading to both COPI and 
COPII vesicles, ERGIC, and cis-Golgi. See 
also the animation, “Nicotine Up-regulates 
nAChRs”: http://www.jgp.org/cgi/content/
full/jgp.201311102/DC2.
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(see Fig. 7, E, F1, and F2). Furthermore, 3-AAA nAChRs 
shifted the NFRET distribution to lower values com-
pared with WT nAChRs (see Fig. 9). Collectively, these 
data suggest that the disruption of the KKK motif re-
sults in deficient retrograde transport of nAChRs be-
tween the Golgi and ER. Although one cannot draw 
specific conclusions about the locus of interference in 
the cyclic processes involving ER, COPII, cis-Golgi, and 
COPI (Orci et al., 1997), the data suggest that this dis-
rupted cycling from the Golgi back to the ER prevents 
up-regulation during exposure to nicotine.
A COPI-dependent process, such as Golgi–ER cycling, is 
necessary for the up-regulation of nAChRs
We asked whether Golgi–ER cycling plays a role in the 
other case of nAChRs (42) that up-regulate at smoking-
relevant concentrations of nicotine. Because the 3 KKK 
motif is unique in nAChR subunits, we exploited a more 
general inhibitor approach, CI-976, to block COPI func-
tion. On 623 nAChRs, CI-976 produced results that 
resembled the pattern observed for 3-WT and 3-AAA 
nAChRs (compare Figs. 8 B1 with 6 D2). Inhibiting 
Golgi–ER cycling prevented up-regulation of 623 
and 42 nAChRs after nicotine treatment. This suggests 
that the cycling of nAChRs between the Golgi and ER is 
necessary for the up-regulation of nAChRs on the PM.
Previous reports indicate that nAChR up-regulation is 
initiated within intracellular compartments and that the 
locus is partially in the ER (see Fig. 10) (Kuryatov et al., 
2005; Sallette et al., 2005; Lester et al., 2009; Miwa et al., 
2011; Srinivasan et al., 2011). The data presented here 
suggest novel aspects of the up-regulation of nAChRs, 
related to general observations that secretory pathways 
have both regulated and constitutive components. The 
increased nAChR density on the PM results from in-
creased ER export of 623 nAChRs (increase in ERES/
COPII, leading to increased insertion events). Previous 
data show that this also occurs in 42 nAChRs (Richards 
et al., 2011; Srinivasan et al., 2011) (depicted in Fig. 10). 
We show here that chronic nicotine also increases the 
number of nAChRs in COPI vesicles (Fig. 7 F1). This 
suggests that in addition to an increase in ER export, 
there is also an increase of retrograde movement of 
nAChRs from the Golgi to the ER. Possibly, 623 and 
42 nAChRs are continually cycled between the ER and 
Golgi through COPI and COPII. This cycling maintains 
a population of nAChRs in the ER that may be neces-
sary for up-regulation. In the absence of nicotine, dis-
ruption of Golgi–ER cycling (either through the 3-AAA 
mutants or use of CI-976) does not affect PM nAChR 
density (Figs. 8 B1 and 6 D2). However, when Golgi–ER 
cycling is inhibited and nicotine is present, nicotine can-
not produce up-regulated PM nAChRs.
How does nicotine exploit a COPI process to up-reg-
ulate PM nAChRs? There are three nonmutually exclu-
sive possibilities. (1) Decreased retrieval of nAChRs 
more 6(non4)3* nAChRs than 64* or 6(non 3)* 
nAChRs. However, there may be more 64* or 
6(non3)* nAChRs on these neurons’ dopaminergic 
terminals in the striatum and accumbens. This is sup-
ported by a report that there are more 64* nAChRs 
on dopaminergic terminals (in striatum and accum-
bens) than there are on dopaminergic cell bodies (in VTA 
and SNc) (Champtiaux et al., 2003).
Second, differing concentrations of nicotine were 
used in the different studies. The doses of nicotine we 
used in mice (2 mg/kg/h and 0.4 mg/kg/h) produce 
plasma concentrations of <500 and <100 nM nicotine, 
respectively (Marks et al., 2004). Perry et al. (2007) used 
a dose (6 mg/kg/day) in rats that produces >500 nM 
plasma nicotine (Nguyen et al., 2004). Our data show 
that 500 nM nicotine decreased the density of 6* nAChRs 
on the PM (Fig. 4, D and F). Therefore, the differences 
observed in our current work and in that of others (Lai 
et al., 2005; Perry et al., 2007; Exley et al., 2013) may be 
caused by the concentration of nicotine used.
The KKK motif of 3 nAChR subunit suggests that a COPI-
mediated retrograde pathway participates in up-regulation
A KKK motif appears in the M3–M4 intracellular loop 
of the 3 nAChR subunit. COPI binds to di-lysine motifs 
(KKxx or KxKxx) (Jackson et al., 2012; Ma and Goldberg, 
2013), and the KKK of the 3 subunit satisfies both mo-
tifs. Measurements of FRET between 623 nAChRs 
and COP indicate that the two molecules approach 
with 100 Å, and this interaction is decreased by mutat-
ing the 3-KKK sequence to 3-AAA (Fig. 9). This sug-
gests that one of these di-lysine motifs in 3 mediates a 
direct interaction between nAChRs and COPI.
We hypothesized that COPI likely plays a role in the 
retrograde transport of 623 nAChRs from the Golgi 
back to the ER. 6* nAChRs with a 3-AAA in place of 
3-KKK failed to up-regulate on the PM in the presence 
of nicotine. We found that the ER localization of the 
6-SEP23AAA nAChRs was decreased compared with 
6-SEP23 nAChRs, suggesting that the 3-AAA motif 
changed the distribution of nAChRs among organelles 
in the early secretory pathway. Indeed, we found that 
the 6-SEP23AAA nAChRs had a significantly higher 
localization within the Golgi than the 6-SEP23 
nAChRs (Fig. 7, C, D1, and D2).
When we add the fact that the number of ERES does 
not differ between the 623 and 623AAA nAChRs in 
basal conditions (e.g., no nicotine) (Fig. 7, A and B), we 
can conclude that the export (via COPII vesicles) of 
nAChRs is not affected. Thus, 623AAA nAChRs are 
exported from the ER at a rate similar to that of 623 
nAChRs. Because export (COPII mediated) is not affected, 
this suggests that retrieval (COPI mediated) is respon-
sible for the disrupted trafficking. This was confirmed 
when we observed significantly fewer 623AAA nAChRs 
in COPI vesicles when compared with 623 nAChRs 
64 Nicotine exploits COPI for up-regulation
The authors have no conflicting financial interests.
Edward N. Pugh Jr. served as editor.
Submitted: 16 September 2013
Accepted: 6 December 2013
R E F E R E N C E S
Araki, Y., D.T. Lin, and R.L. Huganir. 2010. Plasma membrane in-
sertion of the AMPA receptor GluA2 subunit is regulated by NSF 
binding and Q/R editing of the ion pore. Proc. Natl. Acad. Sci. USA. 
107:11080–11085. http://dx.doi.org/10.1073/pnas.1006584107
Asokan, A., and M.J. Cho. 2002. Exploitation of intracellular pH 
gradients in the cellular delivery of macromolecules. J. Pharm. Sci. 
91:903–913. http://dx.doi.org/10.1002/jps.10095
Azam, L., U.H. Winzer-Serhan, Y. Chen, and F.M. Leslie. 2002. 
Expression of neuronal nicotinic acetylcholine receptor subunit 
mRNAs within midbrain dopamine neurons. J. Comp. Neurol. 
444:260–274. http://dx.doi.org/10.1002/cne.10138
Baddick, C.G., and M.J. Marks. 2011. An autoradiographic survey 
of mouse brain nicotinic acetylcholine receptors defined by null 
mutants. Biochem. Pharmacol. 82:828–841. http://dx.doi.org/10
.1016/j.bcp.2011.04.019
Benwell, M.E., D.J. Balfour, and J.M. Anderson. 1988. Evidence 
that tobacco smoking increases the density of ()-[3H]nicotine 
binding sites in human brain. J. Neurochem. 50:1243–1247. http://
dx.doi.org/10.1111/j.1471-4159.1988.tb10600.x
Brandizzi, F., and C. Barlowe. 2013. Organization of the ER-Golgi 
interface for membrane traffic control. Nat. Rev. Mol. Cell Biol. 
14:382–392. http://dx.doi.org/10.1038/nrm3588
Breese, C.R., M.J. Marks, J. Logel, C.E. Adams, B. Sullivan, A.C. 
Collins, and S. Leonard. 1997. Effect of smoking history on [3H]
nicotine binding in human postmortem brain. J. Pharmacol. Exp. 
Ther. 282:7–13.
Brown, W.J., H. Plutner, D. Drecktrah, B.L. Judson, and W.E. Balch. 
2008. The lysophospholipid acyltransferase antagonist CI-976 
inhibits a late step in COPII vesicle budding. Traffic. 9:786–797. 
http://dx.doi.org/10.1111/j.1600-0854.2008.00711.x
Brunzell, D.H., K.E. Boschen, E.S. Hendrick, P.M. Beardsley, and 
J.M. McIntosh. 2010. -conotoxin MII-sensitive nicotinic acetylcho-
line receptors in the nucleus accumbens shell regulate progressive 
ratio responding maintained by nicotine. Neuropsychopharmacology. 
35:665–673. http://dx.doi.org/10.1038/npp.2009.171
Champtiaux, N., C. Gotti, M. Cordero-Erausquin, D.J. David, C. 
Przybylski, C. Léna, F. Clementi, M. Moretti, F.M. Rossi, N. Le 
Novère, et al. 2003. Subunit composition of functional nicotinic 
receptors in dopaminergic neurons investigated with knock-out 
mice. J. Neurosci. 23:7820–7829.
Drenan, R.M., R. Nashmi, P.I. Imoukhuede, H. Just, S. McKinney, 
and H.A. Lester. 2008. Subcellular trafficking, pentameric assem-
bly, and subunit stoichiometry of neuronal nicotinic acetylcholine 
receptors containing fluorescently labeled 6 and 3 subunits. Mol. 
Pharmacol. 73:27–41. http://dx.doi.org/10.1124/mol.107.039180
Exley, R., M.A. Clements, H. Hartung, J.M. McIntosh, M. Franklin, 
I. Bermudez, and S.J. Cragg. 2013. Striatal dopamine transmis-
sion is reduced after chronic nicotine with a decrease in 6-nico-
tinic receptor control in nucleus accumbens. Eur. J. Neurosci. 
38:3036–3043. http://dx.doi.org/10.1111/ejn.12298.
Flores, C.M., S.W. Rogers, L.A. Pabreza, B.B. Wolfe, and K.J. Kellar. 
1992. A subtype of nicotinic cholinergic receptor in rat brain is 
composed of 4 and 2 subunits and is up-regulated by chronic 
nicotine treatment. Mol. Pharmacol. 41:31–37.
Jackson, K.J., J.M. McIntosh, D.H. Brunzell, S.S. Sanjakdar, and M.I. 
Damaj. 2009. The role of alpha6-containing nicotinic acetylcho-
line receptors in nicotine reward and withdrawal. J. Pharmacol. Exp. 
Ther. 331:547–554. http://dx.doi.org/10.1124/jpet.109.155457
from the Golgi produces an increased number of Golgi-
resident nAChRs but a reduced number of ER-resident 
nAChRs. Individual nAChRs therefore spend a smaller 
fraction of time in the ER. Perhaps this renders them 
less available for pharmacological chaperoning by nico-
tine (Fig. 10 A). Such chaperoning seems to be rela-
tively inefficient, even though it takes place at nicotine 
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for activation of PM nAChRs. This inefficiency could 
occur because binding of nicotine must await the dis-
sociation of a competing endogenous chaperone protein 
such as lynx1 (Miwa et al., 2012). (2) Pharmacological 
chaperoning by nicotine does stabilize pentameric 
nAChRs in the ER (Whiteaker et al., 1998; Sallette et al., 
2005) but is nonetheless a pathological process that 
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quired for efficient exit from the Golgi to the PM. If the 
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control checks in the Golgi, they would be targeted for 
retrieval back to the ER via a COPI-dependent process. 
(3) An intriguing possibility is that nicotine may enter 
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nAChRs reside in COPI and/or COPII vesicles (Fig. 10 B). 
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cause the ER and cis-Golgi have nearly neutral lumenal 
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studied here.
Golgi–ER cycling as a new mechanistic target  
for drug discovery
Discovery of the role played by Golgi–ER cycling in both 
623 and 42 nAChRs may eventually provide ad-
ditional avenues for nicotine addiction therapies. A hy-
pothetical small molecule designed to bind to the KKK 
and disrupt COPI binding would prevent the Golgi–ER 
cycling in a manner similar to observations in this work. 
This inhibition of Golgi–ER cycling would prevent the 
up-regulation of 3-containing nAChRs and may pro-
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clinical promise (Watkins et al., 1999; Rauhut et al., 
2003; Yoshimura et al., 2007). In the search for potential 
therapeutics, the selective expression pattern of 623 
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the targeting of 3 more selective than a drug that in-
hibits Golgi–ER cycling in general.
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